Investigational drug · Phase 3
Zovegalisib
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for PIK3CA Mutation, HER2- Negative Breast Cancer, Hormone Receptor Positive Tumor.
Phase 3Last checked: Nov 20, 2026Latest source record: Nov 5, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "Zovegalisib"
First trial start
2025
Aug 26, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Zovegalisib", any sponsor or status.
Conditions studied
As listed on its trial records.
- PIK3CA Mutation
- HER2- Negative Breast Cancer
- Hormone Receptor Positive Tumor
- Breast Cancer
- Metastatic Breast Cancer
- Advanced Breast Cancer
Approved drugs for the same conditions: Breast cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "Zovegalisib" as an intervention, largest first.
- Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast CancerPivotal-lookingRecruiting
Relay Therapeutics, Inc.Industry
NCT06982521 · 540 participants (planned) · Start Aug 26, 2025 · Primary completion Apr 30, 2028
Drug: Zovegalisib; Capivasertib and 1 more · For: PIK3CA Mutation; HER2- Negative Breast Cancer; Hormone Receptor Positive Tumor and 3 more
Sites: Gilbert, Arizona; Beverly Hills, California; Duarte, California · 254 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Zovegalisib for PIK3CA-driven vascular and lymphatic malformations: a drug evaluation.
Seront E, Van Damme A, Coulie J, et al. · Expert Opin Investig Drugs 2026
Also in development for PIK3CA Mutation
- RLY-2608Phase 21 trial
Relay Therapeutics, Inc. · PIK3CA-Related Overgrowth Spectrum (PROS), Lymphatic Malformations, Vascular Malformations
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.